4-Sep-2026
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
Globe Newswire (Tue, 14-Jul 6:02 AM ET)
PRNewswire (Tue, 14-Jul 6:00 AM ET)
Globe Newswire (Tue, 14-Jul 6:00 AM ET)
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
Globe Newswire (Wed, 8-Jul 2:00 AM ET)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of September 4, 2026, SPRO stock price declined to $1.21 with 358,891 million shares trading.
SPRO has a beta of 0.88, meaning it tends to be less sensitive to market movements. SPRO has a correlation of 0.03 to the broad based SPY ETF.
SPRO has a market cap of $70.46 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, BUSM, QQQS, PRFZ.
SPRO has underperformed the market in the last year with a price return of -43.5% while the SPY ETF gained +19.8%. SPRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.4% and -0.8%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
SPRO support price is $1.18 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.